Calamos Advisors’s Pulmonx LUNG Stock Holding History

Calamos Advisors’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-41,111	Closed	-$685K	–	1286
2022 Q3	$685K	Buy	+41,111	New	+$757K	﹤0.01%	990

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

Calamos Advisors's LUNG Position: Q4 2022 in Review

Calamos Advisors sold out of Pulmonx (LUNG) in Q4 2022, closing a stake of 41,111 shares — an estimated $685K sold.

Calamos Advisors first reported a position in LUNG in Q3 2022 and held it in 1 quarter. The position peaked at $685K in Q3 2022. 116 funds tracked by Wall St. Rank hold LUNG as of Q4 2022.

Calamos Advisors reported no remaining Pulmonx position as of Q4 2022 after selling out during the quarter.
Calamos Advisors sold 41,111 Pulmonx shares in Q4 2022, an estimated $685K.
Calamos Advisors first reported a position in Pulmonx in Q3 2022 and held it in 1 quarter.
Calamos Advisors's Pulmonx position peaked at $685K in Q3 2022.
116 funds tracked by Wall St. Rank held Pulmonx as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.